In vivo cytokine production and recombinant interleukin 2 immunotherapy: an insight into the possible mechanisms underlying clinical responses
Open Access
- 1 June 1994
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 69 (6) , 1130-1135
- https://doi.org/10.1038/bjc.1994.222
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Cytokines in tumour therapyBritish Journal of Surgery, 1992
- Recombinant interleukin-2 treatment in patients with metastatic colorectal cancer: Effect on natural cytotoxicityCancer Immunology, Immunotherapy, 1992
- Inhibition of Macrophage-activating Cytokines is Beneficial in the Acute Septic ResponseAnnals of Surgery, 1991
- The Role of Prostaglandin E2 in Immune Suppression Following InjuryAnnals of Surgery, 1991
- Antitumor activity of recombinant interleukin 6 in mice.The Journal of Experimental Medicine, 1990
- Experience with the Use of High-Dose Interleukin-2 in the Treatment of 652 Cancer PatientsAnnals of Surgery, 1989
- A soluble ’anchorminus‘ interleukin 2 receptor suppresses in vitro interleukin 2-mediated immune responsesImmunology Letters, 1988
- Modulation of endothelial cell hemostatic properties by tumor necrosis factor.The Journal of Experimental Medicine, 1986
- Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.The Journal of Experimental Medicine, 1982
- Interleukin-2 augments natural killer cell activityNature, 1981